Biopharma is training for AI

Drug companies used to hire a small artificial intelligence team and leave the rest of the lab alone. In 2025, executives started treating artificial intelligence more like spreadsheet software: something chemists, manufacturing staff, and clinical teams are all expected to use in daily work. (pharmtech.com) Drug development is a long filter. Researchers screen huge numbers of molecules, test which ones hit the right target, then spend years checking whether the same molecule can be made reliably and safely at scale. (pharmtech.com) Artificial intelligence fits that process because much of it is pattern hunting. A model can scan chemical structures, lab results, and manufacturing records faster than a human team can read them one by one. (pharmtech.com) The bottleneck is no longer just buying software. Patrick Lavery’s December 25, 2025 report in Pharmaceutical Technology said the industry’s unresolved barrier is full adoption, which is why companies shifted from pilot projects to practical employee training. (pharmtech.com) That training push showed up alongside a wave of partnerships. Pharmaceutical Technology’s 2025 review pointed to deals across drug discovery, manufacturing, supply chains, and vaccine research, which means artificial intelligence is moving through the whole pipeline instead of sitting in one research corner. (pharmtech.com) Consultants were seeing the same gap from the outside. An EY-Parthenon and Microsoft report released at BioAsia 2025 said artificial intelligence was already changing discovery, clinical trials, and precision medicine, but widespread implementation still depended on organizations learning how to scale it. (ey.com) The reason this matters is that drug companies do not fail only because a molecule is useless. Many drugs land in a murkier zone where some patients improve, others barely respond, and nobody can fully explain the split. (ynetnews.com) That is where immune atlases come in. An immune atlas is a detailed map of the body’s defense cells, built cell by cell, so researchers can see which cell states show up in disease and which ones shift after treatment. (ynetnews.com) Immunai, a biotech company in Tel Aviv, is building an artificial-intelligence-powered immune atlas to explain how therapies behave inside the body. Ynet reported on April 9, 2026 that the company is trying to answer why a drug can look promising in theory and still produce only partial benefit in real patients. (ynetnews.com) Academic groups are building the same kind of maps at research scale. A Nature Medicine paper published in February 2026 used more than 6.5 million immune cells from 1,047 patients across 19 inflammatory diseases to model inflammation in circulating immune cells. (nature.com) Another Nature paper published in February 2026 described an atlas platform that links gene activity to T cell behavior, giving researchers a more precise way to engineer immune cells for cancer treatment. T cells are the immune system’s attack dogs, and the atlas helps show which settings make them aggressive against tumors without pushing them into exhaustion. (nature.com) So the new story is not that biopharma discovered artificial intelligence. The new story is that companies are training ordinary staff to use it while researchers build maps detailed enough to show why a drug only half-works, which is the kind of answer the industry has spent decades trying to get. (pharmtech.com) (ynetnews.com)